The Case for Outsourcing Biologics Process Development - Four reasons why outsourcing may be the best option, and key factors to consider when selecting a provider. - BioPharm International

ADVERTISEMENT

The Case for Outsourcing Biologics Process Development
Four reasons why outsourcing may be the best option, and key factors to consider when selecting a provider.


BioPharm International
Volume 21, Issue 12

REFERENCES

1. PriceWaterhouseCoopers. Pharma 2020: The Vision—Which Path Will You Take? London: PriceWaterhouseCoopers.2007

2. Visiongain. The World Biotech Market 2005—A visiongain report. London: Visiongain. 2007

3. Viswanathan S. A year of deals, partnering and growth. Pharm Form Qual. 2005 October;7(6):22–26.

4. John Jackson RM. Macroeconomics. Roseville, NSW: McGraw-Hill Book Company Australia Pty Ltd; 2001.

5. Aranha H, Wheelwright SM. . Transition from business process outsourcing to knowledge process outsourcing. BioPharm Int. 2007 May supplement: Guide to Outsourcing; p. 58–62.

6. Datamonitor. R&D Strategies. London: Datamonitor. 2007.

7. Bingham J. Global CROs are product development partners. Melbourne: Kendle International Inc. 2007 [cited 2007 Dec 11]. Available from: http://www.biomelbourne.org/1113.98.html.

8. Downey W. Biopharmaceutical contractor selection. Contract Pharma. 2007 April;58–63.

9. Hieber D. Six essential qualities of a bio-outsourcing partner. Contract Pharma. 2007 April;64–71.

10. BioPlan Associates. 4th annual report and survey of biopharmaceutical manufacturing capacity and production. A study of biotherapeutics developers and contract manufacturing organizations. Rockville, MD: BioPlan Associates; 2006.

11. Shahani S. Business opportunity report. Pharmaceutical contract manufacturing and research. Norwalk, CT: Business Communications Company; 2005.

12. Langer ES. Biopharmaceutical production outsourcing matures. Greater percentage of biomanufacturers contracting out for flexibility. BioProcess Int. 2007 Feb;. 32–37.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines
Source: BioPharm International,
Click here